Overview: TNF-alpha TestIntroduction: The TNF-alpha Test measures TNF-alpha levels to assess inflammation or autoimmune diseases, helping diagnose conditions causing joint pain or fatigue. Affecting 1 in 100 people with autoimmune issues, elevated TNF-alpha poses diagnostic challenges due to overlap with other conditions. Following 2023 American College of Rheumatology (ACR) guidelines, it uses ELISA for high accuracy, supporting immunology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in rheumatology.
Other Names: TNF-alpha Level Test, Inflammation Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: TNF-alpha testing began in the 1980s with research by Beutler, who identified its role in inflammation. ELISA advancements by R&D Systems improved detection, surpassing earlier bioassays.
Purpose: Measures TNF-alpha levels to assess inflammation or autoimmune diseases, guides anti-inflammatory therapy, and evaluates patients with joint pain, aiming to manage symptoms.
Test Parameters: TNF-alpha levels
Pretest Condition: No special preparation required. Collect serum or plasma. Report history of autoimmune issues.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document joint pain or fatigue. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., organ damage), and sample collection risks.
Procedural Considerations: Uses ELISA to measure levels, requiring labs with plate readers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest inflammation or autoimmunity, guiding therapy. Early treatment might prevent flares, while untreated cases lead to worsening. Normal levels may require other tests.
Specialist Consultation: Consult a rheumatologist for interpretation.
Additional Supporting Tests: CRP, ANA, or imaging to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False positives possible with acute infection.
References: ACR Guidelines, 2023; Journal of Immunology, Beutler B, 2022.
